The Wistar Institute

Other

Dorothee Herlyn

Hilary Koprowski

Meenhard Herlyn

Laszlo Otvos

Elaine C DeFreitas

Alban J Linnenbach

Rajasekharan Somasundaram

Rajasekaran Somasundaram

Rajasckharan Somasundaram

Elaine Defreitas

Compositions and methods for treating melanoma are provided. Compositions include BRAF-based peptides, alone or admixed with T helper peptides. Other compositions include nucleic acid sequences encoding the BRAF-based peptides, alone or admixed with nucleic acid sequences T helper peptides. Dendritic cells pretreated with the BRAF-based peptides, alone or admixed with T helper peptides, are also provided. These compositions are useful to treat melanoma, optionally co-administered with antibodies to checkpoint inhibitors or molecules that mimic the action of such antibodies.

Methods and compositions for treating melanoma

Novel BRAFmutant peptides or a pharmaceutically acceptable salt thereof, that induce MHC Class I-dependent cytotoxic T cell responses in mammals are useful in prophylactic, diagnostic and therapeutic treatments for melanoma. Such compounds are also useful in drug development for non-peptide mimics of the compounds described herein and in the development of therapeutic or diagnostic antibodies.

A three-dimensional reconstruct model containing solid layers of collagen and fibroblasts closely mimic the condition of patients in vivo, preserving in vivo phenotypic and functional characteristics of the cells. Reconstructs can be used to detect cellular migration, including active migration of cytotoxic T lymphocytes towards tumor cells, which can be measured by detecting tumor cell lysis. Reconstructs also can be used to identify factors that influence migration of cells, including chemokines that influence migration of cytotoxic T lymphocytes, as well as to identify tumor antigens.

Methods and compositions for monitoring cell migration and identifying clinically relevant cytotoxic T lymphocyte activity

The present invention describes novel soluble variants of type I membrane protein GA733-2 and methods of making and using them. In addition, the present invention describes a method of converting type I membrane proteins into secretory proteins which may be used for active immunotherapy against carcinomas and as reagents in the detection of GA733-2 expression on tumor cells.

Soluble variants of type I membrane proteins, and methods of using them

Two stable cytolytic T lymphocyte cell lines and a clone are established from two primary colorectal carcinoma patients. A method for generating stable anti-colorectal carcinoma CTL clones and cell lines includes the step of stimulating the lymphocytes of a patient with minimal or no clinical evidence of colorectal carcinoma in culture with irradiated autologous primary colorectal carcinoma tumor cells, interleukin-2, and either autologous lymphocytes or autologous EBV-B cells.

Cytolytic T-cell clones against colorectal carcinoma

Three murine monoclonal anti-idiotype antibodies which functionally mimic GD2 are described. These antibodies are useful in compositions for inducing a CD4 T cell response to cancers characterized by high density GD2 expression and in the diagnosis of high density GD2 expression.

GD2 anti-idiotypic antibodies and uses thereof

A therapeutic method for treating human tumors in vivo is provided wherein lentinan is administered to the patient followed by treatment with anti-tumor monoclonal antibodies.

Human tumor therapy using beta (1-3) glucanlentinan and anti-tumor

A method of inducing an immunological response to solid tumors is provided wherein anti-idiotype antibodies presenting an internal image of a tumor or antigen are administered to a patient. Monoclonal anti-idiotype antibodies and immortal B lymphocytes that produce them are also provided.

Growing community of inventors

Wynnewood, PA, United States of America

Dorothee Herlyn